FEDS launch experience GLP-1 weight loss medications

The federal government may not have closed the window to pay the GLP-1 weight loss such as OzemPIC and Zepbound after all. According to the Trump administration, the Trump administration is to conduct an experiment that allows some people to cover obesity medications covered by medical care and medical care plans.

Washington Post first break The news on Friday morning, after I got documents from the medical care services and medical aid centers that define the plan. This would enable Medicare Part D to cover the drugs for “weight management”, starting next year. If the experiment goes well, the road may pave the way for medical coverage and medical care on a large scale of these expensive but effective drugs.

Since things are now standing, medicare cannot cover any direct medications to treat obesity, including the most recent GLP-1 factors such as vocations (the active ingredient in OzemPIC, Wegovy), Tirzepatide (Mounjaro and Zepbound). Programs have a deadline in providing coverage for people who take Ozambian drugs similar to diabetes or some obesity conditions, such as heart disease.

Last year, Biden Administration Proposal A base designed to end this restriction, and open the coverage of about 7 million Americans on medical care and medical aid by 2026. In April this year, despite the Trump administration Decline The completely proposed rule. However, Minister of Health Robert F. Kennedy Junior, who was previously criticize In the past, OzemPIC explained, at the time that the White House was still considering a “framework” to expand the coverage.

According to the Washington Post, Medicare and Medicaid CenterOrganization is an organization in charge of finding ways to reduce health care costs and improve patient care – it will be responsible for the experiment. Some details of the plan, including the exact standards of eligibility, may remain in the air, because the government can provide a window for public suspension and additional modification if it chooses. It is currently shown, the experiment is expected to last for at least five years. According to what was received, Medicaid will be able to provide coverage that starts in April 2026, while Medicare plans can do so in January 2027.

The latest GLP-1 drugs, such as the poultry, has proven more effective in helping people lose weight than diet and exercise alone. But its high costs and limited insurance coverage have hindered many people to get these treatments or stay in the long run (some users are also unable to withstand the common intestinal side effects they cause). However, this proposed plan is the latest sign that these cost problems improve.

Prices of the list of medicines or similar medicines Start To drop recently. For example, you are expected to agree with the American neighbor on the upper floor of Canada He depends The first performance of OzemPIC early next year (maybe he will not do so It is happening Until 2030 in the United States, though). The arrival of competitors most likely to these drugs early Next year It is also expected to reduce prices in general.